Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inmune Bio (INMB) Shares Outstanding (2017 - 2025)

Inmune Bio's Shares Outstanding history spans 9 years, with the latest figure at $26.6 million for Q3 2025.

  • For Q3 2025, Shares Outstanding rose 19.9% year-over-year to $26.6 million; the TTM value through Sep 2025 reached $26.6 million, up 19.9%, while the annual FY2024 figure was $22.3 million, 24.12% up from the prior year.
  • Shares Outstanding for Q3 2025 was $26.6 million at Inmune Bio, roughly flat from $26.6 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $26.6 million in Q2 2025 and bottomed at $14.9 million in Q1 2021.
  • The 5-year median for Shares Outstanding is $17.9 million (2022), against an average of $19.3 million.
  • The largest annual shift saw Shares Outstanding surged 38.95% in 2021 before it changed 0.0% in 2023.
  • A 5-year view of Shares Outstanding shows it stood at $17.8 million in 2021, then rose by 0.58% to $17.9 million in 2022, then increased by 0.03% to $18.0 million in 2023, then grew by 24.12% to $22.3 million in 2024, then rose by 19.32% to $26.6 million in 2025.
  • Per Business Quant, the three most recent readings for INMB's Shares Outstanding are $26.6 million (Q3 2025), $26.6 million (Q2 2025), and $22.9 million (Q1 2025).